SARS-CoV-2 Infection Hospital Inclusion Criteria

Maia I.S., Marcadenti A., Veiga V.C., Miranda T.A., Gomes S.P., Carollo M.B., Negrelli K.L., Gomes J.O., Tramujas L., Abreu-Silva E.O., Westphal G.A., Fernandes R.P., Horta J.G., Oliveira D.C., Flato U.A., Paoliello R.C., Fernandes C., Zandonai C.L., Coelho J.C., Barros W.C., Lemos J.C., Bolan R.S., Dutra M.M., Gebara O.C., Lopes A.T., Alencar Filho M.S., Arraes J.A., Hamamoto V.A., Hernandes M.E., Golin N.A., Santos T.M., Santos R.H., Damiani L.P., Zampieri F.G., Gesto J., Machado F.R., Rosa R.G., Azevedo L.C., Avezum A., Lopes R.D., Souza T.M., Berwanger O, & Cavalcanti A.B. (2023). Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trial. Lancet Regional Health - Americas, 20, 100466.